UCB to acquire Ra Pharmaceuticals for $2.1B
The Brussels-based drugmaker said the acquisition of Ra would boost its potential for leadership in the autoimmune disease myasthenia gravis, as both companies have drugs in Phase III development for it.
The Brussels-based drugmaker said the acquisition of Ra would boost its potential for leadership in the autoimmune disease myasthenia gravis, as both companies have drugs in Phase III development for it.